Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.51 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.46 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.46 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.46 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.43 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8344942 | 0.78 | HTT (0.60) | HTTPOLBFGFR1ROCK1MKNK1 | |
| SCHEMBL29602591 | 0.74 | HTT (0.55) | HTTPOLBFGFR1ROCK1MKNK1 | |
| SCHEMBL30524297 | 0.72 | HTT (0.62) | HTTPOLBFGFR1ROCK1MKNK1 | |
| SCHEMBL2465676 | 0.72 | MKNK2 (0.67) | HTTPOLBFGFR1ROCK1MKNK1 | |
| SCHEMBL30402227 | 0.71 | HTT (0.88) | HTTPOLBFGFR1ALDH1A1 | |
| SCHEMBL3417306 | 0.71 | HTT (0.73) | HTTPOLBFGFR1ROCK1MKNK1 | |
| SCHEMBL3419279 | 0.71 | HTT (0.88) | HTTPOLBFGFR1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL2491050 | 0.71 | MKNK2 (0.65) | HTTPOLBFGFR1ROCK1MKNK1 | |
| SCHEMBL9025863 | 0.70 | PIK3CB (0.68) | HTTPOLBFGFR1ROCK1MKNK1 | |
| Benzene SCHEMBL14876970 | 0.70 | HTT (1.00) | HTTFGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1247810-B1 | Novel benzotriazoles anti-inflammatory compounds | PFIZER PROD INC (US) | 2005-09-07 | — | — | EP | disclosed |
| US-6664395-B2 | Benzotriazole compoundsn are the potent inhibitors of MAP kinases, preferably p38 kinase. They are useful for treating inflammation, osteoarthritis, rheumatoid arthritis, cancer, reperfusion, ischemia | PFIZER INC | 2003-12-16 | — | — | US | disclosed |
| US-20030078432-A1 | Novel benzotriazoles anti-inflammatory compounds | PFIZER INC. | 2003-04-24 | — | — | US | disclosed |
| EP-1247810-A1 | Novel benzotriazoles anti-inflammatory compounds | Pfizer Products Inc. (US) | 2002-10-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078432-A1 | Novel benzotriazoles anti-inflammatory compounds | MAPK1, JAK1, RUNX1 | HTT 375/4885POLB 3146/4885FGFR1 911/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.